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Abstract 
 
Purpose. Recent routine testing for liver function and anti-mitochondrial antibodies increased the 45 
number of newly diagnosed patients with primary biliary cirrhosis (PBC). This study investigated the 
prognosis of asymptomatic PBC patients, focusing on age difference, to clarify its effect on the 
prognosis of PBC patients. 
Methods. The study is a systematic cohort analysis of 308 consecutive patients diagnosed with 
asymptomatic PBC. We compared prognosis between the elderly (55 years or older at the time of 50 
diagnosis) and the young patients (<55 years). The mortality rate was also compared with that of age- 
and gender-matched general population.  
Results. The elderly patients showed higher aspartate aminotransferase to platelet ratio, and lower 
alanine aminotransferase than the young (P<0.01, and P=0.03, respectively). The two groups showed 
similar values of alkaline phosphatase and immunoglobulin M. Death of the young patients was more 55 
likely to be due to liver failure (71%), while the elderly might die from other causes before occurrence 
of liver failure (88%, P<0.01), especially from malignancies (35%). The mortality rate of the elderly 
patients was not different from that of the general population (standardized mortality ratio, 1.1; 95% 
confidence interval, 0.6-1.7), although this rate was significantly higher than that of the young patients 
(P=0.044).  60 
Conclusions. PBC often presents more advanced disease in the elderly patients than the young. 
However, the mortality rate of the elderly patients is not different from that of the general population.  
 
Key words. primary biliary cirrhosis, age difference, and mortality rate 
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Introduction 65 
 
Primary biliary cirrhosis (PBC) is a chronic cholestatic disease characterized by progressive 
destruction of the small septal and interlobular bile ducts (1-3). Chronic cholestasis may result in 
hepatic fibrosis and portal hypertension, which may eventually progress to hepatic failure or 
gastrointestinal bleeding. Thirty years ago, most patients diagnosed with PBC showed liver cirrhosis 70 
and disease-related symptoms (4-6). The overall survival of PBC patients was 10-15 years, which was 
significantly less than that of age- and gender-matched controls from the general population (7-10).  
 Recent routine testing for liver function and anti-mitochondrial antibodies (AMA) has increased 
the number of newly diagnosed cases of asymptomatic PBC (11). There are several prognostic studies 
of these asymptomatic patients, suggesting that a significant proportion are in the early stage of PBC 75 
and might respond more favorably to medication without further disease progression for several years 
(2, 11, 12). The studies of the clinical significance of anti-nuclear antibodies (ANA) in PBC indicated 
that PBC-specific ANAs, such as Sp100, promyelocytic leukemia proteins, gp210, and p62 correlate 
with disease activity and might be a marker of poor prognosis (13). The only accepted index to 
estimate patient survival is the Mayo risk score, which is very useful in advanced cases, however, of 80 
limited use in patients with early disease (14).  
Recent studies on age differences in patients with autoimmune hepatitis (AIH) showed more 
frequent presentation of elderly patients with severe disease (15, 16). However, the relationship 
between age at diagnosis and prognosis of PBC patients remains unclear. The present study 
investigated the proposal that young and elderly asymptomatic PBC patients have different prognoses. 85 
To test this, we compared clinical features including prognosis between the two age groups of patients. 
We also compared the mortality rates for PBC patients with those of age- and gender-matched 
general-population.  
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Patients and Methods 90 
 
Patients 
This study is a systematic cohort analysis of 308 consecutive patients (271 females and 37 males) 
diagnosed with asymptomatic PBC at Okayama University and affiliated hospitals from 1980 to 2004. 
A diagnosis of PBC was made based on any two of the following criteria: (1) positive test for AMA, (2) 95 
biochemical evidence of cholestasis, and (3) liver biopsy compatible with the diagnosis (12). The 
presence of AMA was determined by indirect immunofluorescence on murine tissue sections (cutoff 
value; 1:40) or enzyme-linked immunosorbent assay against beef pyruvate dehydrogenase. Pruritus, 
jaundice (bilirubin >2 mg/dl), bleeding varices, severe general fatigue, and ascites were defined as 
symptoms associated with disease progression. Patients showing serum positivity for hepatitis B 100 
surface antigen or anti-hepatitis C virus (HCV) antibodies, daily ethanol use of more than 60 grams, or 
other signs of liver injury, were excluded from this study. The study was in accordance with the Helsinki 
Declaration, and approved by the ethical committee of the institutes. All patients provided informed 
consent.  
 105 
Histological evaluation 
Histological stages were evaluated according to the criteria of Ludwig et al. (1). Briefly, stage I was 
defined by portal inflammation confined to the portal triads; stage II by portal and periportal 
inflammation without septal fibrosis or bridging necrosis; stage III by lobular fibrosis and/or bridging 
necrosis; and stage IV corresponded to cirrhosis.  110 
 
Survival State 
All patients were examined for physical status and development of disease-related symptoms. Patients 
who had not visited our hospitals in the previous 6 months were contacted by letter or telephone and 
asked to provide details of recent medications and any disease-related symptoms by using 115 
questionnaires. If they visited other hospitals, we also asked them about the results of any endoscopy 
or imaging studies. In cases that the patient had died, the date and cause of death were recorded. 
Only the patients followed for at least 1 year were included in the prognostic analysis. Survival 
statistics were compared between PBC patients and the general population (age- and 
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gender-matched), using a standardized mortality ratio (SMR). The SMR was calculated by dividing the 120 
observed number of deaths by the expected number of deaths, as calculated from gender- and age 
(5-year)-ranked mortality among the Japanese general population in 2003 published by the Statistics 
and Information Department of Japan Ministry of Health and Welfare (17). The 95% confidence 
intervals (CI) for the SMR values were assumed by Poisson’s distribution.  
 125 
Statistical Analysis 
Data are expressed as mean±SD or median (range). Patient characteristics were compared among 
the groups by using the Chi-square, Mann-Whitney U, and Kruskal-Wallis tests. The proportional 
harzards model was utilized to estimate the effects of patients’ characters on survival. The survival 
rates and disease progression to symptomatic PBC were estimated by the Kaplan-Meier method, and 130 
compared with the log rank test. A P value of less than 0.05 was considered significant.  
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Results 
 
Patient Characteristics 135 
Table 1 lists the clinical characteristics of the patients recruited in this study. The age of patients in this 
study showed a single peak in the fifties, with a median age at diagnosis of 56 years, which is 
agreement with several previous studies (11, 18, 19). Based on these results, the patients were 
divided into two groups: the young group (<55 years old) and the elderly group (≥55 years). Most 
patients were female (88.3%). Interestingly, the male patients had a peak age distribution in the sixties 140 
(63 ± 11 years), which was significantly higher than that of the female patients (55 ± 11 years, P < 0.01, 
Mann-Whitney U test). The frequencies of positive AMA or ANA showed no significant difference 
between the groups. The two groups showed similar values of alkaline phosphatase (ALP), but the 
young had higher alanine aminotransferase (ALT) than the elderly (P =0.03, Mann-Whitney U test). 
The elderly group had significantly higher aspartate aminotransferase (AST) to platelet ratio and lower 145 
platelet count than the young group (P < 0.01, Mann-Whitney U test).  
 
Survival of PBC patients 
The survival of PBC patients was evaluated with 282 patients who were followed for at least 1 year. 
The mean period of follow up was 81 ± 50 months (86 ± 53 months in the young group and 77 ± 47 150 
months in the elderly group respectively). This period was defined as the time between diagnosis and 
either death or the latest confirmation of survival. The accumulated observation was 1904 person-year 
accounting for 92.6% of the total potential follow-up. The rate of disease progression to symptomatic 
PBC was significantly higher in the elderly group than the young group (P = 0.023, log rank test, Figure 
1). At 10 years follow up, 19% of the young and 35% of the elderly patients would progress to 155 
symptomatic PBC. Causes of death are summarized in Table 2. Liver transplantation was considered 
a liver-related death when calculating the SMR. Twenty-four patients died or had a liver transplant. 
Liver failure and malignancies were the leading causes of death in the both groups. Death of the young 
patients was more likely to be due to liver failure (71%), while the elderly patients might die from other 
causes before occurrence of liver failure (88%, P<0.01, Fisher exact probability test), especially from 160 
malignancies other than Hepatocellular carcinoma (HCC; 35%). Two of the three patients who died of 
HCC were likely to have advanced liver diseases, because they were in histological stage 3 at the time 
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of diagnosis and the tumors were detected in longer observation than 10 years. The incidence rate of 
HCC was 0.13% annually. Figure 2 shows that overall survival rate was significantly lower in the 
elderly group than the young group (P = 0.044, log rank test). At 10 years follow up, 4.3% of the young 165 
and 16% of the elderly patients would be dead. The results indicated that the elderly patients died from 
other causes before occurrence of liver failure, and their survival rate was significantly lower than that 
of the young patients. We evaluated the effects of patients’ characters on prognosis with the 
proportional hazards model (Table 3). Old age, male gender, high AST to platelet ratio, and high ALP 
might predict short survival in the univariate analysis. The multivariate analysis, adjusting with logistic 170 
likelihood ratio test, indicated that high AST to platelet ratio, but not old age was a significant predictive 
factor.  
 
Comparison of mortality with age- and gender-matched general population 
Table 4 showed the overall mortality and the mortality for liver-related deaths, liver-unrelated deaths, 175 
and malignancies. The overall mortality rate of PBC patients was slightly higher than that of the 
general population (SMR, 1.6; 95%CI, 1.0-2.4). Importantly, the overall mortality rate of the elderly 
group was not different from that of the general population (SMR, 1.1; 95%CI, 0.6-1.7). Liver-related 
mortality was significantly higher among PBC patients (SMR, 47; 95%CI, 23-86), especially the young 
patients (SMR, 218; 95%CI, 71-509) than in the general population, while liver-unrelated mortality 180 
among PBC patients was not different from that in the general population (SMR, 1.0; 95%CI, 0.5-1.6). 
The mortality for malignancies among PBC patients was twice as high as expected (SMR, 2.3; 95%CI, 
1.2-4.2), as shown in previous reports (20, 21). These results indicated that the young patients were 
more likely to die from liver-related causes during the course of PBC, and that the elderly patients were 
just as likely to die from liver-unrelated causes with survival expectancies similar to the age- and 185 
gender-matched general population. 
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Discussion 
 
Routine testing for liver function and AMA increased the number of newly diagnosed cases of 
asymptomatic PBC, and several recent studies attempted to clarify the prognosis of those 190 
asymptomatic patients, which has not been fully understood. The relationship between age at 
diagnosis and prognosis remains unclear in PBC patients. We hypothesized that age difference might 
have an important role in prognosis of PBC patients, because age difference on disease progression 
has been reported in other chronic liver diseases such as chronic hepatitis C (22) and AIH (15). The 
present study is a systematic cohort analysis of a large group of asymptomatic PBC patients, and the 195 
first to investigate the prognosis of PBC patients more precisely by dividing the patients according to 
their age at diagnosis.  
Considering the possibility of lead time bias that some of the elderly patients had delayed 
diagnosis in advanced stage, we analyzed the correlations between age at diagnosis and AST to 
platelet ratio, in order to estimate the effect of age difference on liver damage, and those were not 200 
significant (R = 0.11; P = 0.065, canonical correlation analysis). There was no significant difference 
between the two groups in histological stage of liver biopsy specimens obtained at the time of 
diagnosis, with approximately half of them defined as stage 1. The age distribution of patients of this 
study is similar to those of other multicenter studies (11, 18, 19). These findings do not indicate that the 
elderly group might involve the patients who had delayed diagnosis of PBC.  205 
In terms of the mortality of asymptomatic PBC patients, there have been several conflicting 
reports. Prince et al. suggested that asymptomatic PBC patients have reduced survival compared with 
the general population, with an SMR >2.5-fold higher than expected deaths (12). Springer et al. 
reported that asymptomatic PBC patients had shortened survival, and only the patients who remained 
asymptomatic survived as well as a matched control population (11). Uddenfeldt et al. showed similar 210 
survival of asymptomatic patients to the general population (23). In the present study, the mortality of 
PBC patients was slightly higher than that of the general population (SMR, 1.6; 95%CI, 1.0-2.4). Our 
analysis, by dividing the patients in the two groups according to their age at diagnosis, clarified that the 
elderly patients had similar SMR to the general population (SMR, 1.1; 95%CI, 0.6-1.7), while the 
mortality rate of the young patients was seven times as high as expected. The influence of age 215 
difference on mortality occurred partly because the mortality rate of the young general population was 
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as low as 0.15% annually, which was one twelfth of that of the elderly general population. The mortality 
rate of the young patients was much higher than that of the young general population, although it was 
significantly lower than that of the elderly patients or the elderly general population.  
The young patients might die from liver failure or receive liver transplant, while the deaths of 220 
the elderly patients were more likely to be due to liver-unrelated causes such as malignancies. The 
elderly patients would develop disease-related symptoms if they lived long enough, but their survival 
might not be affected by the subsequent development of disease-related symptoms, since a 
considerable number of them died of liver-unrelated causes before occurrence of liver failure. These 
results indicated that the young patients might die from liver-related causes during the course of PBC, 225 
and that the elderly patients were just as likely to die from liver-unrelated causes with survival 
expectancies similar to the age- and gender-matched general population. The reports on cancer risk of 
PBC patients suggested that there is a small increase in overall cancer incidence and mortality in PBC 
patients (20, 21). Our results are consistent with those reports, showing that overall mortality for 
malignancies was higher than the general population (SMR, 2.3; 95%CI, 1.2-4.2). The mortality for 230 
malignancies was slightly higher both in the young and the elderly groups than the general population, 
although this increase was not statistically significant. Except for hepatocellular carcinoma, it is unlikely 
that there is a high excess incidence for PBC patients from any cancer at a particular site. Periodical 
check-up for malignancies should be necessary for good management of PBC patients.  
Many different drugs have been used to slow disease progression in PBC patients, with 235 
variable results. Ursodeoxycholic acid (UDCA) delays histological progression (24-29), and prolongs 
survival without liver transplantation (30, 31). However, these findings were challenged in two 
independent meta-analyses (32, 33), showing that UDCA did not affect survival. Most patients in the 
present study (276 patients, 89%) were treated with UDCA over the course of the disease. There was 
no significant difference in use of drugs between the young and elderly groups (Table 1). UDCA might 240 
be adequate as the initial treatment for the elderly patients, because they do not reduce survival at 
least. On the other hand, the young patients need active management to prevent from liver failure, 
because our results indicated that they may develop disease-related symptoms at relatively young 
age, and may not survive as well as the general population. Bezafibrate and immunosuppressants 
were additionally prescribed for 43 and 51 patients, respectively in the present study. Our data were 245 
not sufficient to assess the survival benefits of these drugs.  
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 In conclusion, age difference should be one of the important factors to predict the prognosis of 
PBC patients, since the mortality rate of PBC patients aged ≥55 years diagnosed at asymptomatic 
stage are not different from those of the general population. The elderly patients may have more 
advanced diseases than the young patients. Death of the young patients was more likely to be due to 250 
liver failure, while the elderly patients died from liver-unrelated causes such as malignancies. Active 
management of liver disease might lead better prognosis of young PBC patients.  
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Table 1: Clinical characteristics of the patients at the time of diagnosis. 
 
 All patients 
(N = 308) 
Young group 
(n = 133) 
Elderly group 
(n = 175) 
 
p 
Age (years) 56 (24 - 83)† 48 (24 - 54)† 63 (55 – 83)†  
Gender (female/male) 272/36 123/10 149/26 0.04 
Liver histology (I/II/III/IV)* 120/67/19/3 59/33/5/1 61/34/14/2 0.28 
Treatment (UDCA/Others/none) 273/10/25 119/5/10 154/5/15 0.86 
Laboratory Data at diagnosis     
AMA (% positive) 78.9 80.5 77.7 0.65 
ANA (% positive) 58.1 57.9 58.3 1 
AST (IU/L) 58 ± 70‡ 57 ± 60‡ 59 ± 78‡ 0.73 
ALT (IU/L) 62 ± 71‡ 72 ± 92‡ 54 ± 49‡ 0.034 
ALP (ratio)** 1.9 ± 1.3‡ 1.8 ± 1.3‡ 2.0 ± 1.3‡ 0.39 
Total bilirubin (mg/dl) 0.7 ± 0.3‡ 0.7 ± 0.4‡ 0.8 ± 0.3‡ 0.02 
Platelet count (x104/mm3) 21.1 ± 6.7‡ 23.3 ± 6.6‡ 19.5 ± 6.3‡ < 0.01 
Total cholesterol (mg/dl) 209 ± 46‡ 207 ± 44‡ 211 ± 47‡ 0.099 
Immunoglobulin G (mg/dl) 1852 ± 560‡ 1817 ± 500‡ 1878 ± 602‡ 0.68 
Immunoglobulin M (mg/dl) 473 ± 332‡ 449 ± 263‡ 492 ± 376‡ 0.71 
AST to Platelet ratio 3.3 ± 5.6‡ 2.5 ± 2.2‡ 4.0 ± 7.0‡ < 0.01 
 
* Histological stage classified by Ludwig et al. (1); ** Expressed relative to the upper limit of normal.  335 
†: Median (range); ‡: Mean ± SD. 
UDCA, ursodeoxycholic acid; AMA, anti-mitochondrial antibody; ANA, anti-nuclear antibody; AST, 
aspartate aminotransferase; ALT, alanine aminotransferase; ALP, alkaline phosphatase. 
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Table 2: Causes of death. 
 340 
Cause of death All patients Young group Elderly group 
Liver-related 10 5 5 
Liver transplantation 1 1 0 
Hepatocellular carcinoma 3 0 3 
Liver failure 6 4 2 
Liver-unrelated 14 2 12 
Malignancies* 8 2 6 
Heart failure 1 0 1 
Cerebrovascular disease 2 0 2 
Pneumonia 3 0 3 
Total deaths or Liver transplantation 24 7 17 
 
*, Malignancies other than hepatocellular carcinoma. 
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Table 3: Analysis of predictive factors on survival with the proportional hazards model. 
 
 Univariate analysis Multivariate analysis 
Factors Odds ratio (Range†) p Odds ratio (Range†) p 
Age (55 years or older) 2.35 (0.96-5.73) 0.061 2.90 (0.78-10.7) 0.11 
Gender (male) 2.94 (1.15-7.53) 0.025 1.71 (0.57-5.17) 0.34 
Liver histology (II/III/IV) 0.748 (0.29-1.90) 0.54   
ALT (higher than 2 fold of ULN) 1.58 (0.66-3.80) 0.30   
ALP (higher than 2 fold of ULN) 2.59 (1.12-6.02) 0.027 1.25 (0.42-3.69) 0.69 
Platelet count (< ULN) 1.43 (0.55-3.73) 0.46   
Total cholesterol (> ULN) 1.00 (0.42-2.39) 0.99   
Immunoglobulin G (> ULN) 1.76 (0.65-4.77) 0.27   
Immunoglobulin M (> ULN) 1.23 (0.51-2.98) 0.64   
AST to Platelet ratio (> 3.0) 4.89 (1.72-13.9) < 0.01 3.42 (1.04-11.2) 0.042 
 
345 
†: 95% confidence interval. 
ULN, the upper limit of normal; ALT, alanine aminotransferase; ALP, alkaline phosphatase; AST, 
aspartate aminotransferase 
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Table 4: Standardized mortality ratio (SMR) of the patients. 350 
 
 All patients 
(N = 282) 
Young group 
(n = 128) 
Elderly group 
(n = 154) 
Overall deaths    
Observed/Expected 24/15 7/1 17/16 
SMR (range)† 1.6 (1.0-2.4) 7.4 (3.0-15.2) 1.1 (0.6-1.7) 
Liver-related deaths    
Observed/Expected 10/0.2 5/0.0 5/0.2 
SMR (range)† 47 (23-86) 218 (71-509) 23 (7.3-53) 
Liver-unrelated deaths    
Observed/Expected 14/14 2/0.9 12/16 
SMR (range)† 1.0 (0.5-1.6) 2.2 (0.3-7.8) 0.8 (0.4-1.3) 
Malignancies    
Observed/Expected 11/4.7 2/0.6 9/6.1 
SMR (range)† 2.3 (1.2-4.2) 3.3 (0.4 -12) 1.5 (0.7-2.8) 
 
†: 95% confidence interval. 
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Figure legends 355 
 
Figure 1: Disease progression rate to symptomatic PBC, stratified by age at diagnosis. 
The rates of disease progression to symptomatic PBC were estimated for both the young and elderly 
groups by the Kaplan-Meier method. The log rank test was used to compare the two rates. The rate of 
disease progression to symptomatic state was significantly higher in the elderly group than the young 360 
group (P = 0.023, log rank test). At 10 years follow up, 19% of the young and 35% of the elderly 
patients would progress to symptomatic state. 
 
Figure 2: Overall survival rate of PBC patients, stratified by age at diagnosis. 
Survival rates of the young and elderly groups were compared by using the Kaplan-Meier method. The 365 
survival curves showed significantly lower mortality in the elderly group than the young group (P = 
0.044, log rank test). At 10 years follow up, 4.3% of the young and 16% of the elderly patients would be 
dead.  
